Dr. James Peyer of ApolloVC discussed tactical paths to bring longevity promoting therapeutics to market as quickly as possible.
The cost of developing a drug is $2.6 billion. Pharma companies need to have each successful drug approved has to pay for ten failed drugs. Each drug from discovery through clinical trials averages out to a cost of $260 million.
Anti-aging companies and anti-aging investors need to focus on an initial aging disease to get approval to treat. They then target a second and third anti-aging disease. After that they can look at trying to follow metformin for general anti-aging approval. Metformin is the first anti-aging treatment that the FDA is looking at for a general antiaging approval.
There is increasing of pharmaceutical company engagement via disease-focused proof of concept trials. This talk was given at the Ending Age-Related Diseases conference in NYC.
Curing all cancers would add 3.5 years to average human lifespan. If anti-aging could delay the start of aging disease from 50 or 60 by two or three decades then this could be ten times better than curing cancer.
$50 billion per year is spent on curing cancer. If medical research was allocated based upon potential impact then anti-aging should be at a funding level of $500 billion per year.
Brian Wang is a prolific business-oriented writer of emerging and disruptive technologies. He is known for insightful articles that combine business and technical analysis that catches the attention of the general public and is also useful for those in the industries. He is the sole author and writer of nextbigfuture.com, the top online science blog. He is also involved in angel investing and raising funds for breakthrough technology startup companies.
He gave the recent keynote presentation at Monte Jade event with a talk entitled the Future for You. He gave an annual update on molecular nanotechnology at Singularity University on nanotechnology, gave a TEDX talk on energy, and advises USC ASTE 527 (advanced space projects program). He has been interviewed for radio, professional organizations. podcasts and corporate events. He was recently interviewed by the radio program Steel on Steel on satellites and high altitude balloons that will track all movement in many parts of the USA.
He fundraises for various high impact technology companies and has worked in computer technology, insurance, healthcare and with corporate finance.
He has substantial familiarity with a broad range of breakthrough technologies like age reversal and antiaging, quantum computers, artificial intelligence, ocean tech, agtech, nuclear fission, advanced nuclear fission, space propulsion, satellites, imaging, molecular nanotechnology, biotechnology, medicine, blockchain, crypto and many other areas.